Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CRACR2A | Q9BSW2 | 13/20 | 0.67 |
| ▸ | IL2 | P60568 | 5/20 | 0.51 |
| ▸ | TNF | P01375 | 1/20 | 0.51 |
| ▸ | STIM1 | Q13586 | 1/20 | 0.51 |
| ▸ | ORAI1 | Q96D31 | 1/20 | 0.51 |
| ▸ | NPC1 | O15118 | 1/20 | 0.47 |
| ▸ | RAB9A | P51151 | 1/20 | 0.47 |
| ▸ | WNT1 | P04628 | 1/20 | 0.38 |
| ▸ | CLK2 | P49760 | 1/20 | 0.38 |
| ▸ | CLK3 | P49761 | 1/20 | 0.38 |
| ▸ | DYRK1A | Q13627 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30096518 | 1.00 | CRACR2A (0.67) | CRACR2AIL2TNFSTIM1ORAI1 | |
| SCHEMBL16660119 | 0.87 | IL2 (0.57) | CRACR2AIL2TNFSTIM1ORAI1 | |
| SCHEMBL15529650 | 0.87 | CRACR2A (0.69) | CRACR2AIL2TNFSTIM1ORAI1 | |
| SCHEMBL30096555 | 0.87 | CRACR2A (0.69) | CRACR2AIL2TNFSTIM1ORAI1 | |
| SCHEMBL30096585 | 0.85 | IL2 (0.53) | CRACR2AIL2TNFSTIM1ORAI1 | |
| SCHEMBL15528875 | 0.85 | CRACR2A (0.61) | CRACR2AIL2TNFSTIM1ORAI1 | |
| SCHEMBL15529390 | 0.85 | IL2 (0.53) | CRACR2AIL2TNFSTIM1ORAI1 | |
| SCHEMBL15528930 | 0.84 | CRACR2A (0.47) | CRACR2AIL2TNFSTIM1ORAI1 | |
| SCHEMBL16660113 | 0.83 | IL2 (0.55) | CRACR2AIL2TNFSTIM1ORAI1 | |
| SCHEMBL15529826 | 0.82 | IL2 (0.57) | CRACR2AIL2TNFSTIM1ORAI1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 23 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20170114060-A1 | NOVEL EFFECTIVE ANTIVIRAL COMPOUNDS AND METHODS USING SAME | NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT | 2017-04-27 | — | — | US | claimed |
| US-20160304507-A1 | SUBSTITUTED PYRAZOLE COMPOUNDS AS CRAC MODULATORS | LUPIN LIMITED (IN) | 2016-10-20 | — | — | US | claimed |
| US-9409898-B2 | Substituted pyrazole compounds as CRAC modulators | LUPIN LIMITED (IN) | 2016-08-09 | — | — | US | claimed |
| WO-2015187827-A1 | NOVEL EFFECTIVE ANTIVIRAL COMPOUNDS AND METHODS USING SAME | THE TRUSTEES OF THE UNIVERSITY OF PENNSYLVANIA (US) | 2015-12-10 | — | — | WO | claimed |
| US-20150111925-A1 | SUBSTITUTED PYRAZOLE COMPOUNDS AS CRAC MODULATORS | LUPIN LIMITED (IN) | 2015-04-23 | — | — | US | claimed |
| EP-2844656-A1 | SUBSTITUTED PYRAZOLE COMPOUNDS AS CRAC MODULATORS | Lupin Limited (IN) | 2015-03-11 | — | — | EP | claimed |
| WO-2013164773-A1 | SUBSTITUTED PYRAZOLE COMPOUNDS AS CRAC MODULATORS | LUPIN LIMITED (IN) | 2013-11-07 | — | — | WO | claimed |
| US-12544371-B2 | Methods and compositions for treating acute lung injury and acute respiratory distress syndrome | CALCIMEDICA, INC. (US) | 2026-02-10 | — | — | US | disclosed |
| WO-2023141523-A1 | METHODS AND COMPOSITIONS FOR TREATING INFLAMMATION INJURY IN THE LUNGS | CALCIMEDICA, INC. (US) | 2023-07-27 | — | — | WO | disclosed |
| US-20230120819-A1 | METHODS AND COMPOSITIONS FOR TREATING ACUTE LUNG INJURY AND ACUTE RESPIRATORY DISTRESS SYNDROME | AVENUE CAPITAL MANAGEMENT II, L.P. | 2023-04-20 | — | — | US | disclosed |
| EP-4121089-A1 | METHODS AND COMPOSITIONS FOR TREATING ACUTE LUNG INJURY AND ACUTE RESPIRATORY DISTRESS SYNDROME | Calcimedica, Inc. (US) | 2023-01-25 | — | — | EP | disclosed |
| WO-2021189013-A1 | METHODS AND COMPOSITIONS FOR TREATING ACUTE LUNG INJURY AND ACUTE RESPIRATORY DISTRESS SYNDROME | CALCIMEDICA, INC. (US) | 2021-09-23 | — | — | WO | disclosed |
| US-20170114060-A1 | NOVEL EFFECTIVE ANTIVIRAL COMPOUNDS AND METHODS USING SAME | NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT | 2017-04-27 | — | — | US | disclosed |
| US-9409898-B2 | Substituted pyrazole compounds as CRAC modulators | LUPIN LIMITED (IN) | 2016-08-09 | — | — | US | disclosed |
| US-9409898-B2 | Substituted pyrazole compounds as CRAC modulators | LUPIN LIMITED (IN) | 2016-08-09 | — | — | US | disclosed |
| US-9409898-B2 | Substituted pyrazole compounds as CRAC modulators | LUPIN LIMITED (IN) | 2016-08-09 | — | — | US | disclosed |
| WO-2015187827-A1 | NOVEL EFFECTIVE ANTIVIRAL COMPOUNDS AND METHODS USING SAME | THE TRUSTEES OF THE UNIVERSITY OF PENNSYLVANIA (US) | 2015-12-10 | — | — | WO | disclosed |
| US-20150111925-A1 | SUBSTITUTED PYRAZOLE COMPOUNDS AS CRAC MODULATORS | LUPIN LIMITED (IN) | 2015-04-23 | — | — | US | disclosed |
| US-20150111925-A1 | SUBSTITUTED PYRAZOLE COMPOUNDS AS CRAC MODULATORS | LUPIN LIMITED (IN) | 2015-04-23 | — | — | US | disclosed |
| US-20150111925-A1 | SUBSTITUTED PYRAZOLE COMPOUNDS AS CRAC MODULATORS | LUPIN LIMITED (IN) | 2015-04-23 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-12544371-B2 | Methods and compositions for treating acute lung injury and acute respiratory distress syndrome | ORAI1, MAVS, CASR | CRACR2A 80/4885IL2 84/4885TNF 82/4885 |
| US-20150111925-A1 | SUBSTITUTED PYRAZOLE COMPOUNDS AS CRAC MODULATORS | ORAI1, RYR2, RYR1 | CRACR2A 127/4885IL2 2916/4885TNF 3547/4885 |
| US-20230120819-A1 | METHODS AND COMPOSITIONS FOR TREATING ACUTE LUNG INJURY AND ACUTE RESPIRATORY DISTRESS SYNDROME | MAVS, ATF1, IL1B | CRACR2A 162/4885IL2 247/4885TNF 82/4885 |
| US-20170114060-A1 | NOVEL EFFECTIVE ANTIVIRAL COMPOUNDS AND METHODS USING SAME | ZC3HAV1, MAVS, EIF2AK2 | CRACR2A 1735/4885IL2 3340/4885TNF 981/4885 |
| US-20160304507-A1 | SUBSTITUTED PYRAZOLE COMPOUNDS AS CRAC MODULATORS | ORAI1, RYR2, RYR1 | CRACR2A 127/4885IL2 2916/4885TNF 3547/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.